OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825

BACKGROUND: Myelotoxicity is a rare but serious side effect of TMZ. In RTOG0825, 16% and 23% of patients experienced grade 3 or higher myelotoxicity during chemoradiation or adjuvant phase, respectively. Our goal was to evaluate risk and validate prediction of myelotoxicity in patients treated with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Armstrong, T. S., Gilbert, M. R., Bondy, M., Sulman, E., Yuan, Y., Zhou, R., Vera, E., Wendland, M., Pugh, S., Scheurer, M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
ORAL PRESENTATIONS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463630/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.033
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak